Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab

The increasing use of immune checkpoint inhibitors, such as nivolumab, a programmed cell death protein 1 (PD-1) inhibitor, for advanced neoplastic disease has revealed significant cutaneous immune-related adverse effects. Herein, we report a case of bullous pemphigoid (BP) secondary to nivolumab the...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsen, Eric, Svoboda, Steven A, Saikaly, Sami K, Missall, Tricia A, Motaparthi, Kiran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491457/
https://www.ncbi.nlm.nih.gov/pubmed/37692698
http://dx.doi.org/10.7759/cureus.43230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491457/
https://www.ncbi.nlm.nih.gov/pubmed/37692698
http://dx.doi.org/10.7759/cureus.43230

Ejemplares similares